Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Telaprevir: Phase IIb data

In the placebo-controlled, European Phase IIb PROVE 2 trial, 65% of 81 telaprevir patients had a sustained viral response

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE